尿検査市場：製品タイプ別、用途別、検査タイプ別、エンドユーザー別、地域別、2024年～2031年

尿検査市場の評価、2024年～2031年

世界の尿検査市場は力強い成長を遂げており、2023年の評価額は42億米ドル、2031年には69億1,000万米ドルに達すると予測され、2024年から2031年までのCAGRは6.1%で成長しています。この成長は、腎臓病や尿路感染症の増加、製品の上市や承認といった主要企業の今後の活動に起因しています。ヘルスケア支出の増加は患者の経済的負担を軽減し、尿検査製品の販売拡大と市場成長を促進します。先進技術や革新的な検査法のイントロダクションは、診断精度の向上と患者の転帰の改善に寄与し、市場をさらに押し上げます。ヘルスケアサービスへのアクセスが拡大し、予防医療が重視されるようになったことが、尿検査製品に対する需要を促進し、市場の拡大と開発を促進しています。

尿検査市場定義/概要

尿検査には、1回の尿サンプルを使って尿中を通過する様々な化合物を検出・測定する様々な検査が含まれます。尿検査は、ヘルスケアプロバイダーによって、肝臓病、腎臓病、糖尿病などの一般的な健康状態のスクリーニングやモニタリング、尿路感染症（UTI）の診断に利用されることが多いです。尿検査は少量の尿サンプルを調べる軽度の検査で、腎臓病、尿路感染症、肝臓病、糖尿病、その他の代謝性疾患のスクリーニングや診断に用いられます。尿検査には、肉眼的検査、化学的評価、顕微鏡的検査の3種類があります。糖尿病や高齢者の増加に伴い、尿検査はますます一般的になっています。

尿検査は尿の外観、濃度、含有量を調べるもので、定期的な健康診断として推奨されています。顕微鏡検査は通常、目視検査や化学検査で異常所見があった場合、またはヘルスケア専門医から特別な指示があった場合に実施されます。尿検査で異常所見が認められた場合は、結果を確認するために再検査が必要となり、診断の確定を助けるために尿検査や血液検査が追加されることもあります。

尿検査市場の成長を促進する要因は何か？

効果的な診断ツールに対する需要は、糖尿病、腎臓病、尿路感染症（UTI）などの慢性疾患の世界の負担の増加によって高まっています。尿検査は、これらの疾患に対する費用対効果が高く非侵襲的なスクリーニング・ツールとして機能し、早期発見とタイムリーな管理を促進します。高齢化社会では、尿路結石や腎機能障害など加齢に関連した疾患にかかりやすくなるため、これらの疾患のモニタリングや管理のための尿検査の需要が高まっています。ヘルスケアに対する意識の高まりと予防医療への注力が、潜在的な健康懸念に対する簡単で便利なスクリーニング・ツールとして尿検査の利用を促進しています。

尿検査技術の技術的進歩は、精度、効率、アクセシビリティを向上させ、市場の成長に大きく寄与しています。このような進歩には、ディップスティックの感度と特異度の向上、迅速なターンアラウンドタイムを実現する自動分析装置、ベッドサイド検査用のポイントオブケア装置などが含まれます。さらに、可処分所得が増加している地域では、尿検査のような予防的検査を受ける傾向が強まり、市場成長に寄与しています。

政府の取り組みや支援は、病気の早期発見や予防ヘルスケアの推進に重要な役割を果たしています。このようなイニシアチブは、尿検査の利用を支援する環境を整えることで、尿検査市場の成長に間接的に寄与しています。これらの要因は、尿検査の既存の広範な使用と相まって、今後数年間の市場の成長軌道の予測に有望なイメージを描いています。全体として、技術の進歩の統合、ヘルスケア意識の高まり、政府の支援策が、尿検査市場の予想成長の原動力となっています。慢性疾患の有病率が世界的に上昇を続ける中、早期発見・早期管理のための重要な診断ツールとしての尿検査の重要性は、ヘルスケアにおける地位をさらに強固なものにすると予想されます。

代替供給源は尿検査市場の売上を減少させるか？

尿検査市場は成長を遂げる一方で、その発展を妨げる潜在的な課題に直面しています。最大の市場シェアを占める定期的なディップスティック検査は、より高度な検査と比較して情報範囲が限られています。この情報不足により、ヘルスケアプロバイダーは特定の状況において、より包括的な他の診断ツールを選択するようになる可能性があり、ディプスティック検査の売上に影響を与えます。

血液検査や画像技術のような他の診断技術の進歩のような代替検査が利用できるようになれば、特定の状況に対してより具体的で詳細な情報を提供できるようになり、場合によっては尿検査からの嗜好の転換につながる可能性があります。

コスト面では、一般的には手ごろな価格であるにもかかわらず、慢性疾患のモニタリングのために尿検査を頻繁に行ったり繰り返したりすると、それに伴う累積コストがかかるため、一部の患者やヘルスケア機関にとっては懸念となる可能性があります。そのため、常に検査を行う場合にはコストがかかり、利用率が低下する可能性があります。

尿検査に対する保険者からの償還方針は、検査費用の全額をカバーするには必ずしも十分ではないかもしれないです。その限界にもかかわらず、主要な診断手段としてディップスティックに過度に依存することは、特定の症例において診断の見落としにつながる可能性があり、尿検査の有効性に対する懸念が高まり、他の診断アプローチの採用に影響を及ぼす可能性があります。技術、費用対効果、適切な利用戦略の改善を通じてこれらの要因に対処することで、市場情勢における同市場の地位はさらに強化される可能性があります。

目次

第1章 尿検査世界市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の尿検査市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 尿検査の世界市場：製品タイプ別

• 概要
• 自動尿分析装置
• 半自動尿分析装置
• ポイントオブケア尿分析装置
• 分注器
• カップ＆容器
• 試薬

第6章 尿検査の世界市場：用途別

• 概要
• 疾病診断
• 妊娠検査
• 薬物検査
• 糖尿病管理
• その他

第7章 尿検査の世界市場：検査タイプ別

• 概要
• 定期検査
• 顕微鏡検査
• 生化学検査
• 沈渣
• 妊娠

第8章 尿検査の世界市場：エンドユーザー別

• 概要
• 病院
• 診療所・診断研究所
• 研究・学術機関
• 在宅医療現場

第9章 尿検査の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の尿検査市場の競合情勢

• 概要
• 企業市場シェア
• ベンダー情勢
• 主な発展戦略

第11章 企業プロファイル

• Siemens AG
• F. Hoffmann-LA Roche Ltd.
• Danaher Corporation
• Sysmex Corporation
• Arkray Inc.
• Acon Laboratories Inc.
• Bio-Rad Laboratories Inc.
• 77 ElektronikaKft.
• Shenzhen Mindray Bio-Medical Electronics Co.
• URIT Medical
• Erba Mannheim
• Trinity Biotech
• BioMaxima S.A.
• Accurex
• Quantimetrix

第12章 付録

• 関連調査

Urinalysis Test Market Valuation - 2024-2031

Strong growth has been witnessed in the Global Urinalysis Test Market, with a valuation of USD 4.2 Billion in 2023 and a projected increase to USD 6.91 Billion by 2031, growing at a CAGR of 6.1% from 2024 to 2031 . This growth is attributed to rising occurrences of kidney diseases and urinary tract infections, coupled with forthcoming activities by key players such as product launches and approvals. Increased healthcare expenditure enhances patient affordability, leading to augmented sales of urinalysis products and encouraging market growth. The market is further propelled by the introduction of advanced technologies and innovative testing methods, contributing to improved diagnostic accuracy and patient outcomes. Expanded access to healthcare services and a growing emphasis on preventive care drive the demand for urinalysis tests, fostering market expansion and development.

Urinalysis Test Market: Definition/Overview

A variety of tests that detect and measure various compounds passing through urine using a single urine sample are included in urinalysis tests. Urinalysis is often utilized by healthcare providers to screen for or monitor common health conditions like liver disease, kidney disease, and diabetes, as well as to diagnose urinary tract infections (UTIs). It is a mild test that examines a small urine sample and may be employed for screening or diagnosing kidney diseases, urinary tract infections, liver problems, diabetes, or other metabolic conditions. Urinalysis incorporates three types of tests, including gross examination, chemical evaluation, and microscopic examination. With the rising prevalence of diabetes and the elderly population, urinalysis testing has become increasingly common.

A urinalysis encompasses checking the appearance, concentration, and content of urine and is recommended as a routine checkup for individuals. Microscopic examination is usually conducted when there is an abnormal finding on the visual or chemical test, or if specifically ordered by a healthcare practitioner. Abnormal findings on a urinalysis may prompt repeat testing to confirm results and may be followed by additional urine and blood tests to aid in establishing a diagnosis.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What Factors are Driving the Growth of the Urinalysis Test Market?

The demand for effective diagnostic tools is fueled by the increasing global burden of chronic conditions such as diabetes, kidney diseases, and urinary tract infections (UTIs). Urinalysis serves as a cost-effective and non-invasive screening tool for these conditions, facilitating early detection and timely management. The aging population is more susceptible to age-related conditions like UTIs and kidney dysfunction, thereby, surging a higher demand for urinalysis for monitoring and managing these conditions. Increasing healthcare awareness and focus on preventative care are driving the utilization of urinalysis as a simple and convenient screening tool for potential health concerns.

Technological advancements in urinalysis technology contribute significantly to market growth by enhancing accuracy, efficiency, and accessibility. These advancements include improved dipstick sensitivity and specificity, automated analyzers with faster turnaround times, and point-of-care devices for bedside testing. Moreover, in regions with increasing disposable incomes, individuals may be more inclined to undergo preventive testing like urinalysis, thereby contributing to market growth.

Government initiatives and support play a crucial role in promoting early disease detection and preventative healthcare. Such initiatives indirectly contribute to the growth of the Urinalysis Test Market by creating a supportive environment for its utilization. These factors, combined with the existing widespread use of urinalysis, paint a promising picture for the projected growth trajectory of the market in the coming years. Overall, the integration of technological advancements, increasing healthcare awareness, and supportive government initiatives are driving forces behind the anticipated growth of the Urinalysis Test Market. As the prevalence of chronic conditions continues to rise globally, the importance of urinalysis as a vital diagnostic tool for early detection and management is expected to further solidify its position in the healthcare landscape.

Will Alternative Sources Plummet Sales of the Urinalysis Test Market?

While experiencing growth, the Urinalysis Test Market is confronted with potential challenges that could hinder its progress. Routine dipstick tests, which hold the largest market share, offer a limited scope of information compared to more advanced tests. This lack of information potentially diverts leading healthcare providers to opt for other, more comprehensive diagnostic tools in specific situations, thus impacting dipstick sales.

Availability of alternative tests, such as advancements in other diagnostic technologies like blood tests and imaging techniques, might offer more specific and detailed information for certain conditions, potentially leading to a preference shift away from urinalysis in some cases.

Cost considerations, despite generally being affordable, could become a concern for some patients or healthcare institutions owing to the cumulative costs associated with frequent or repeated urinalysis for monitoring chronic conditions. Thus, the cost when constantly testing could lower its utilization.

Reimbursement policies from insurers for urinalysis might not always be sufficient to cover the full cost of the test, potentially discouraging healthcare providers from ordering them as frequently. Over-reliance on dipsticks as a primary diagnostic tool, despite their limitations, might lead to missed diagnoses in certain cases, raising concerns about the efficacy of urinalysis and influencing the adoption of other diagnostic approaches. Addressing these factors through improved technology, cost-effectiveness, and appropriate utilization strategies could further strengthen the market's position in the healthcare landscape.

Category-Wise Acumens

Which Product Type Category Holds the Dominant Market Share in the Urinalysis Test Market?

In the Urinalysis Test Market, the dominant market share is typically held by automated urine analyzers. These instruments are characterized by their sophisticated design, which enables the automation of the urine sample analysis process, resulting in rapid and accurate results. Equipped with advanced technology, such as optical sensors and software algorithms, they facilitate comprehensive testing of various parameters including pH, protein, glucose, ketones, and specific gravity. Automated Urine Analyzers play a pivotal role in streamlining the urinalysis process within clinical laboratories. They possess the capability to handle large volumes of samples with high throughput and efficiency.

By automating various steps, they significantly reduce the need for manual intervention, thereby minimizing the risk of errors and ensuring consistent and reliable results across multiple tests. Additionally, these analyzers often incorporate integrated data management systems, which enable seamless documentation and interpretation of test results.

The adoption of automated urine analyzers contributes to improved workflow efficiency in clinical laboratories, allowing healthcare professionals to process a greater number of samples in a shorter amount of time. This not only enhances laboratory productivity but also facilitates timely diagnosis and treatment decisions for patients. Furthermore, the automation of the analysis process reduces the burden on laboratory staff, enabling them to focus on more complex tasks and ensuring optimal utilization of resources. The prevalence of automated urine analyzers in the Urinalysis Test Market underscores their significance in modern clinical laboratory settings. Their advanced features, coupled with the ability to streamline workflows and ensure accurate results, position them as indispensable tools for healthcare providers seeking to deliver high-quality diagnostic services efficiently.

Which Factors Contribute to the Routine Urinalysis Test Type Holding the Highest Market Share in the Urinalysis Test Market?

Broad applicability characterizes routine urinalysis tests, making them widely used for general screening purposes across various healthcare settings such as hospitals, clinics, and laboratories. These tests provide comprehensive insights into overall health and are routinely incorporated into medical check-ups and pre-operative assessments, leading to their extensive adoption and market dominance.

Simplicity and accessibility are key features of routine urinalysis tests, as they require minimal technical expertise for performance and interpretation. This accessibility makes them suitable for utilization by healthcare professionals across different specialties, including primary care physicians, nurses, and laboratory technicians. The availability of dipstick-based tests allows for swift and convenient on-site testing, further enhancing their accessibility.

Routine urinalysis tests are noted for their cost-effectiveness, presenting an attractive option for healthcare providers aiming to optimize resource utilization. Their affordability permits routine screening of large populations, including asymptomatic individuals and those at risk of developing urinary tract infections or kidney diseases, which contributes significantly to their high market share.

Despite their simplicity, routine urinalysis tests offer valuable diagnostic information for a wide spectrum of health conditions, encompassing urinary tract infections, kidney diseases, diabetes, and dehydration. Their capability to detect abnormalities such as proteinuria, hematuria, and glycosuria renders them indispensable tools for early disease detection and monitoring, further consolidating their market dominance. The continued prominence of routine urinalysis tests is supported by established clinical guidelines and protocols, reinforcing their use as standard screening tools in clinical practice. Healthcare providers are well-acquainted with their interpretation and integration into patient care pathways, which sustains their utilization and market leadership. In summary, the routine urinalysis test is dominating in the Urinalysis Test Market owing to its easy applicability, simplicity, cost-effectiveness, diagnostic utility, and adherence to established guidelines and protocols.

Country/Region Wise Acumens

Could North America Drive an Increase in Sales within the Urinalysis Test Market?

North America is characterized by its advanced healthcare infrastructure, comprising state-of-the-art medical facilities, advanced laboratory equipment, and skilled healthcare professionals. This infrastructure enables the widespread adoption and utilization of urinalysis tests, consequently driving sales across the region.

North America grapples with a notable burden of chronic diseases such as diabetes, kidney diseases, and urinary tract infections (UTIs). Urinalysis tests play a pivotal role in the early detection, monitoring, and management of these conditions, thereby fostering increased demand and subsequent sales.

Stringent regulatory standards, particularly in the United States, ensure the quality and accuracy of medical tests, including urinalysis. Adherence to these standards enhances consumer confidence in the reliability and efficacy of urinalysis tests, thereby stimulating sales within the region. Moreover, North America dedicates a substantial portion of its healthcare expenditure towards diagnostic testing and preventive healthcare measures. This significant investment supports the utilization of urinalysis tests as integral components of routine health screenings and disease management protocols, thereby propelling sales growth.

The region benefits from a robust research and development ecosystem, driving continuous innovations in urinalysis technology. These advancements lead to the development of more sophisticated and user-friendly testing solutions, ultimately enhancing the performance, accuracy, and efficiency of urinalysis tests and further bolstering sales within North America. North America's advanced healthcare infrastructure, rising burden of chronic diseases, stringent regulatory standards, substantial healthcare expenditure, and continuous technological advancements collectively position the region as a significant driver of sales growth within the Urinalysis Test Market.

Will the Sales of the Urinalysis Test Market Fare well in Europe?

Europe is characterized by a robust healthcare infrastructure with well-established medical facilities and a skilled workforce, facilitating the widespread adoption and utilization of urinalysis tests across various healthcare settings. This infrastructure is conducive to creating a favorable market environment.

Europe is confronted with a significant burden of chronic diseases such as diabetes, kidney diseases, and urinary tract infections (UTIs), akin to other regions. Urinalysis tests are utilized as crucial diagnostic tools for the early detection, monitoring, and management of these conditions, thereby driving their demand and subsequent sales within the region.

A strong emphasis is placed on preventive healthcare and disease management in Europe, leading to a high demand for diagnostic tests, including urinalysis. Government initiatives and healthcare policies further support the utilization of urinalysis tests as part of routine health screenings and disease prevention programs, thereby fostering sales growth. Europe hosts several leading medical device manufacturers and research institutions, driving innovation in urinalysis technology. This continuous advancement in technology results in the development of more sophisticated and accurate testing solutions, enhancing the performance and reliability of urinalysis tests and further bolstering their sales within the region.

The region's stringent regulatory standards ensure the quality and safety of medical devices, including urinalysis tests, enhancing consumer confidence and facilitating market growth. With its strong healthcare infrastructure, high burden of chronic diseases, emphasis on preventive healthcare, innovation in technology, and regulatory framework, Europe is poised to witness a favorable sales performance in the Urinalysis Test Market.

Competitive Landscape

As the demand for urinalysis tests continues to grow globally, understanding the competitive landscape becomes imperative for stakeholders aiming to navigate this evolving market effectively. This analysis, characterized by comprehensive assessments of market players, strategies, and product offerings, provides valuable insights into the competitive positioning and future trajectories of key market participants. Moreover, it facilitates strategic decision-making and identifies potential opportunities for market expansion and differentiation within the highly competitive landscape of the Urinalysis Test Market.

Some of the prominent players operating in the Urinalysis Test Market include:

Siemens AG, Hoffmann-LA Roche Ltd., Danaher Corporation, Sysmex Corporation, Arkray Inc., Acon Laboratories Inc., Bio-Rad Laboratories Inc., 77 ElektronikaKft., Shenzhen Mindray Bio-Medical Electronics Co., URIT Medical, Erba Mannheim, Trinity Biotech, BioMaxima S.A., Accurex, Quantimetrix.

Latest Developments

In October 2023, the launch of its Atellica(R) CH 1000 point-of-care urine analyzer was announced by Siemens Healthineers, to provide fast and reliable urine analysis results in various clinical settings.

In September 2023, FDA 510(k) clearance for its Cobas(R) u 600 urine analyzer was received by Roche Diagnostics, highlighting advancements in automation and efficiency for large-scale urine testing in laboratories.

In August 2023, a partnership with Paige AI to develop AI-powered solutions for automated urinalysis image analysis was formed by Abbott Laboratories, potentially improving accuracy and efficiency in urine sediment examination.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL URINALYSIS TEST MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL URINALYSIS TEST MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL URINALYSIS TEST MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Automated Urine Analyzers
• 5.3 Semi-Automated Urine Analyzers
• 5.4 Point-of-Care Urine Analyzers
• 5.5 Dipsticks
• 5.6 Cups & Containers
• 5.7 Reagents

6 GLOBAL URINALYSIS TEST MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Disease Diagnosis
• 6.3 Pregnancy Testing
• 6.4 Drug Testing
• 6.5 Diabetes Management
• 6.6 Others

7 GLOBAL URINALYSIS TEST MARKET, BY TEST TYPE

• 7.1 Overview
• 7.2 Routine
• 7.3 Microscopic
• 7.4 Biochemical
• 7.5 Sediment
• 7.6 Pregnancy

8 GLOBAL URINALYSIS TEST MARKET, BY END-USERS

• 8.1 Overview
• 8.2 Hospitals
• 8.3 Clinics & Diagnostic Laboratories
• 8.4 Research & Academic Institutes
• 8.5 Home Care Settings

9 GLOBAL URINALYSIS TEST MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 France
  • 9.3.3 UK
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10 GLOBAL URINALYSIS TEST MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Share
• 10.3 Vendor Landscape
• 10.4 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Siemens AG
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 F. Hoffmann-LA Roche Ltd.
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Danaher Corporation
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Sysmex Corporation
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Arkray Inc.
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Acon Laboratories Inc.
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Bio-Rad Laboratories Inc.
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 77 ElektronikaKft.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Shenzhen Mindray Bio-Medical Electronics Co.
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 URIT Medical
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments
• 11.11 Erba Mannheim
  • 11.11.1 Overview
  • 11.11.2 Financial Performance
  • 11.11.3 Product Outlook
  • 11.11.4 Key Developments
• 11.12 Trinity Biotech
  • 11.12.1 Overview
  • 11.12.2 Financial Performance
  • 11.12.3 Product Outlook
  • 11.12.4 Key Developments
• 11.13 BioMaxima S.A.
  • 11.13.1 Overview
  • 11.13.2 Financial Performance
  • 11.13.3 Product Outlook
  • 11.13.4 Key Developments
• 11.14 Accurex
  • 11.14.1 Overview
  • 11.14.2 Financial Performance
  • 11.14.3 Product Outlook
  • 11.14.4 Key Developments
• 11.15 Quantimetrix
  • 11.15.1 Overview
  • 11.15.2 Financial Performance
  • 11.15.3 Product Outlook
  • 11.15.4 Key Developments

12 Appendix

• 12.1 Related Research